Patents Issued in January 28, 2014
  • Patent number: 8637241
    Abstract: This invention relates to a method for detecting, (i) malignant astrocytoma from normal brain tissue (ii) glioblastoma and anaplastic astrocytoma (iii) primary glioblastoma and secondary glioblastoma (iv) progressive pathway and denovo pathway comprises determining the level of expression of miRNAs listed in table 2, 3, 4, 5, wherein a higher or lower level of expression of miRNAs in the test sample as compared to the control sample differentiates and kit for characterizing a) malignant astrocytoma from normal brain tissue cell comprising reagent capable of specifically detecting the level of expression of the genes of miRNAs and instructions for using said kit for characterizing malignant astrocyoma from normal brain tissue cells b) glioblastoma from anaplastic astrocytoma comprising reagent capable of specifically detecting the level of expression of the genes of miRNAs and instructions for using said kit for characterizing glioblastoma from anaplastic astrocyoma c) primary glioblastoma from secondary gliob
    Type: Grant
    Filed: March 31, 2011
    Date of Patent: January 28, 2014
    Assignees: Department of Biotechnology, Indian Institute of Sciences
    Inventors: Kumaravel Somasundaram, Soumya Aliga Mahabala Rao, Vani Santosh
  • Patent number: 8637242
    Abstract: Provided are methods and apparatuses for performing sequencing using droplet manipulation, for example, via electrowetting-based techniques. Also provided are integrated methods and apparatuses for performing sample preparation and sequencing on the same apparatus. In addition, provided are methods of reducing reagent waste and preloaded consumable cartridges comprising reagents for sample preparation and/or sequencing.
    Type: Grant
    Filed: November 6, 2012
    Date of Patent: January 28, 2014
    Assignee: Illumina, Inc.
    Inventors: Min-Jui Richard Shen, Robert C. Kain, Kenneth M. Kuhn, AmirAli Hajhossein Talasaz, Arash Jamshidi
  • Patent number: 8637243
    Abstract: A method for replicating and amplifying a target nucleic acid sequence is described. A method of the invention involves the formation of a recombination intermediate without the prior denaturing of a nucleic acid duplex through the use of a recombination factor. The recombination intermediate is treated with a high fidelity polymerase to permit the replication and amplification of the target nucleic acid sequence. In preferred embodiments, the polymerase comprises a polymerase holoenzyme. In further preferred embodiments, the recombination factor is bacteriophage T4 UvsX protein or homologs from other species, and the polymerase holoenzyme comprises a polymerase enzyme, a clamp protein and a clamp loader protein, derived from viral, bacteriophage, prokaryotic, archaebacterial, or eukaryotic systems.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: January 28, 2014
    Assignee: The Penn State Research Foundation
    Inventors: Stephen J Benkovic, Frank Salinas
  • Patent number: 8637244
    Abstract: The invention relates to procedure and methods of determining a susceptibility to cardiac arrhythmia, including Atrial Fibrillation, Atrial Flutter and Stroke, by assessing the presence or absence of alleles at polymorphic markers found to be associated with Atrial Fibrillation, Atrial Flutter and Stroke. The invention further relates to kits encompassing reagents for assessing such markers, and diagnostic methods, uses and procedures for utilizing such susceptibility markers.
    Type: Grant
    Filed: December 5, 2007
    Date of Patent: January 28, 2014
    Assignee: deCODE Genetics ehf.
    Inventors: Anna Helgadottir, Daniel Gudbjartsson
  • Patent number: 8637245
    Abstract: The present invention refers to the detection of EGFR mutations in a blood (serum/plasma) sample from a subject. The method comprises: (i) obtaining the DNA from said sample; (ii) amplifying the nucleic acid sequence corresponding to a specific region of the EGFR gene by means of PCR using a Protein-Nucleic Acid probe; 10 and (iii) detecting said mutation.
    Type: Grant
    Filed: July 20, 2007
    Date of Patent: January 28, 2014
    Assignee: Pangea Biotech, S.A.
    Inventors: Rafael Rosell Costa, Miguel Taron Roca
  • Patent number: 8637246
    Abstract: The present invention relates to methods, compositions and kits concerning resistance to treatment with an anti-cancer agent, specifically an inhibitor of BRAF. In particular embodiments, the invention concerns mutations in a BRAF sequence that confer resistance to a BRAF inhibitor. Identification of such mutations in a BRAF sequence allows the identification and design of second-generation BRAF inhibitors. Methods and kits for detecting the presence of a mutant BRAF sequence in a sample are also provided.
    Type: Grant
    Filed: February 22, 2011
    Date of Patent: January 28, 2014
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Levi Garraway, Caroline Emery
  • Patent number: 8637247
    Abstract: The present disclosure relates to methods of identifying target nucleic acids by using coded molecules and its analysis by translocation through a nanopore. Generally, coded molecules are subject to a target polynucleotide dependent modification. The modified coded molecule is detected by isolating the modified coded molecules from the unmodified coded molecules prior to analysis through the nanopore or by detecting a change in the signal pattern of the coded molecule when analyzed through the nanopore.
    Type: Grant
    Filed: August 21, 2012
    Date of Patent: January 28, 2014
    Assignee: Applied Biosystems, LLC
    Inventors: Muhammad Sharaf, Timothy Woudenberg, Khairuzzaman Bashar Mullah
  • Patent number: 8637248
    Abstract: In amplifying a region containing two allelic genes, the polymorphism of one of the allelic genes is positioned at or near the 3? end of an amplification primer, so that the chain would extend only from one of the two primers, one that matches the mutant type nucleotide(s) and one that matches the wild-type nucleotide(s). The other primer is unaffected by the allelic genes but is positioned to include the other allelic gene in the amplicon. The PCR amplifies only the target genomic DNA having one specific allele of the first allelic gene. The technique exploits the fact that the haplotype of the first and the second allelic genes can be determined if the allele of the second allelic gene in the amplicon can be identified.
    Type: Grant
    Filed: November 30, 2007
    Date of Patent: January 28, 2014
    Assignee: Canon Kabushiki Kaisha
    Inventors: Shin-ichiro Takahama, Yuri Mizutani
  • Patent number: 8637249
    Abstract: The disclosed invention is related to compositions, kits and methods comprising one or more oligomers targeting 16S rRNA target nucleic acid from Campylobacter species jejuni, coli and/or lari. Compositions include amplification oligomers, detection probe oligomers and/or target capture oligomers. Kits and methods comprise at least one of these oligomers.
    Type: Grant
    Filed: November 16, 2009
    Date of Patent: January 28, 2014
    Assignee: Gen-Probe Incorporated
    Inventors: Michael R. Reshatoff, Jr., Jennifer J. Bungo, Shannon K. Kaplan, James J. Hogan
  • Patent number: 8637250
    Abstract: Composition and methods for amplifying and detecting solution-state polynucleotide targets in a single device are described. In one aspect, a method for a coupled isothermal amplification and detection process utilizes a coated solid support, including a solid substrate, a cationic layer, and a plurality of target-specific probes attached to the coated solid support. Polynucleotide targets in the sample are amplified by an isothermal amplification process involving in situ hybridization onto the coated solid support. The entire process can be carried out with a high degree of specificity under low salt conditions in less than one hour. Further aspects of the present invention include methods for coupled hybridization/detection of polynucleotide targets, coated silicon biosensors optimized for use with the coupled detection systems to provide visual detection of polynucleotide targets under visible light conditions, and kits for practicing in the above described methods.
    Type: Grant
    Filed: May 13, 2010
    Date of Patent: January 28, 2014
    Assignee: Great Basin Scientific
    Inventor: Robert Delmar Jenison
  • Patent number: 8637251
    Abstract: A nucleic acid quantification method that uses a microchip for nucleic acid amplification reaction, the microchip including an inlet through which a liquid is introduced from outside, a plurality of reaction regions provided as reaction sites of a nucleic acid amplification reaction, and a channel through which the liquid introduced through the inlet is supplied into each of the reaction regions, wherein the likelihood of the nucleic acid amplification reaction varies between the reaction regions, includes: flowing a detection target nucleic acid chain-containing solution through the channel and introducing the solution into each of the reaction regions to perform a nucleic acid amplification reaction; and detecting an amplification product in each of the reaction regions to specify the reaction regions in which the nucleic acid amplification reaction occurred.
    Type: Grant
    Filed: September 13, 2011
    Date of Patent: January 28, 2014
    Assignee: Sony Corporation
    Inventors: Tomoteru Abe, Yuji Segawa, Junji Kajihara, Tomohiko Nakamura, Masaki Sato
  • Patent number: 8637252
    Abstract: This invention relates, in part, to methods and compositions for determining altered susceptibility of a human immunodeficiency virus (“HIV”) to the non-nucleoside reverse transcriptase inhibitors (“NNRTIs”) efavirenz (“EFV”), nevirapine (“NVP”), and delavirdine (“DLV”), the nucleoside reverse transcriptase inhibitor AZT, and the integrase strand transfer inhibitors diketo acid 1, diketo acid 2, and L-870,810 by detecting the presence of a mutation or combinations of mutations in the gene encoding HIV reverse transcriptase that are associated with altered susceptibility to the anti-HIV drugs.
    Type: Grant
    Filed: November 15, 2011
    Date of Patent: January 28, 2014
    Assignee: Monogram Biosciences, Inc.
    Inventors: Soumi Gupta, Signe Fransen, Ellen Paxinos, Neil T. Parkin
  • Patent number: 8637253
    Abstract: The present invention features novel, diverse, hybrid and engineered recombinase enzymes, and the utility of such proteins with associated recombination factors for carrying out DNA amplification assays. The present invention also features different recombinase ‘systems’ having distinct biochemical activities in DNA amplification assays, and differing requirements for loading factors, single-stranded DNA binding proteins (SSBs), and the quantity of crowding agent employed.
    Type: Grant
    Filed: November 30, 2011
    Date of Patent: January 28, 2014
    Assignee: Alere San Diego, Inc.
    Inventors: Olaf Piepenburg, Niall A. Armes, Mathew James David Parker
  • Patent number: 8637254
    Abstract: The presently disclosed subject matter provides methods of diagnosis of cancer or adverse pregnancy outcomes in a subject by measuring amounts of one or more RNAs present in cancer-derived exosomes isolated from a biological sample from the subject.
    Type: Grant
    Filed: February 24, 2010
    Date of Patent: January 28, 2014
    Assignee: University of Louisville Research Foundation, Inc.
    Inventors: Douglas D. Taylor, Cicek Gercel-Taylor
  • Patent number: 8637255
    Abstract: The nucleic acid sequences of adeno-associated virus (AAV) serotype 1 are provided, as are vectors and host cells containing these sequences and functional fragments thereof. Also provided are methods of delivering genes via AAV-1 derived vectors.
    Type: Grant
    Filed: March 16, 2011
    Date of Patent: January 28, 2014
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: James M. Wilson, Weidong Xiao
  • Patent number: 8637256
    Abstract: The invention relates to an immunodiagnostic method for determining the release of neurotensin into the circulation of mammals based on the selective determination of an immunoreactivity of the N-terminal portion of a mammal proneurotensin (PNT immunoreactivity) in a serum or plasma sample of a mammal; this immunoreactivity is not neurotensin or neuromedin immunoreactivity.
    Type: Grant
    Filed: January 25, 2006
    Date of Patent: January 28, 2014
    Assignee: Sphingotec GmbH
    Inventor: Andrea Ernst
  • Patent number: 8637257
    Abstract: The present invention relates to methods for identifying agents capable of inhibiting the expression or activity of proteins involved in the processes modulating osteoclastogenesis, which inhibition is useful in the prevention and/or treatment of bone and joint degenerative diseases and diseases involving aberrant activity or differentiation of osteoclasts. In particular, the present invention provides methods for identifying agents for use in the prevention and/or treatment of rheumatoid arthritis.
    Type: Grant
    Filed: June 19, 2008
    Date of Patent: January 28, 2014
    Assignee: Galapagos NV
    Inventors: Reginald Christophe Xavier Brys, Nick Ernest René Vandeghinste
  • Patent number: 8637258
    Abstract: The present invention relates to a method of producing an antibody that cross-reacts with multiple KIR2DL polypeptides and neutralizes the inhibitory activity of such polypeptides.
    Type: Grant
    Filed: June 10, 2010
    Date of Patent: January 28, 2014
    Assignees: Novo Nordisk A/S, University of Genoa, Innate Pharma, S.A.
    Inventors: Soren Berg Padkjaer, Alessandro Moretta, Mariella Della Chiesa, Pascale Andre, Laurent Gauthier, Peter Andreas Nicolai Reumert Wagtmann
  • Patent number: 8637259
    Abstract: The invention relates to the identification of carboxylic acids, present in human sweat, as natural ligands of a specific subgroup of seven olfactory receptor (OR) belonging to class 1 within the OR classification. The invention encompasses the use of the interaction of OR polypeptides and carboxylic acids as the basis of screening assays for agents that specifically modulate the activity of the seven ORs of the invention.
    Type: Grant
    Filed: February 9, 2011
    Date of Patent: January 28, 2014
    Assignee: ChemCom S.A.
    Inventors: Pierre Chatelain, Alex Veithen
  • Patent number: 8637260
    Abstract: Antibodies that are specific for human Ra1A that is phosphorylated at one or both of Ser183 and Ser194 are described as various methods such antibodies, including diagnostic methods and screening methods.
    Type: Grant
    Filed: May 16, 2011
    Date of Patent: January 28, 2014
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: William C. Hahn, Laura Corral, Anna A. Sablina
  • Patent number: 8637261
    Abstract: The present invention, provides a flow cytometry apparatus for the detection of particles from a plurality of samples comprising: means for moving a plurality of samples comprising particles from a plurality of respective source wells into a fluid flow stream; means for introducing a separation gas between each of the plurality of samples in the fluid flow stream; and means for selectively analyzing each of the plurality of samples for the particles. The present invention also provides a flow cytometry method employing such an apparatus.
    Type: Grant
    Filed: August 14, 2012
    Date of Patent: January 28, 2014
    Assignee: STC.UNM
    Inventors: Larry A Sklar, Bruce Edwards, Frederick Kuckuck
  • Patent number: 8637262
    Abstract: Provided are purified and isolated VEGF-C polypeptides capable of binding to at least one of KDR receptor tyrosine kinase (VEGFR-2) and Flt4 receptor tyrosine kinase (VEGFR-3); analogs of such peptides that have VEGF-C-like or VEGF-like biological activities or that are VEGF or VEGF-C inhibitors; polynucleotides encoding the polypeptides; vectors and host cells that embody the polynucleotides; pharmaceutical compositions and diagnostic reagents comprising the polypeptides; and methods of making and using the polypeptides. Methods of inhibiting endothelial cell proliferation are also provided.
    Type: Grant
    Filed: October 5, 2012
    Date of Patent: January 28, 2014
    Assignee: Vegenics Pty Limited
    Inventors: Kari Alitalo, Vladimir Joukov
  • Patent number: 8637263
    Abstract: A screening method for identifying compounds with anti-emetic properties by evaluating binding affinity and efficacy of the compounds with respect to the 5-HT1a, 5-HT1d, and 5-HT7 receptors.
    Type: Grant
    Filed: October 14, 2011
    Date of Patent: January 28, 2014
    Assignee: Epiomed Therapeutics, Inc.
    Inventors: David Reed Helton, David Brian Fick, Ernest H. Pfadenhauer
  • Patent number: 8637264
    Abstract: Methods of using microarrays to simplify analysis and characterization of genes and their function are provided. Such methods can be used to identify and characterize antibodies having binding affinity for a specific target antigen. A method of determining gene expression at the protein level by contacting an array of characterized or uncharacterized antibodies on a solid surface with one or more proteins and identifying the antibodies to which said protein(s) binds also is provided. This method can be used to compare the protein expression in two different populations of cells, such as normal cells and cancer cells or resting cells and stimulated cells. In addition, a method of determining gene expression at the protein level by contacting a microarray of nucleic acid samples derived from a variety of different sources with one or more nucleic acid probes then identifying the sample or samples to which the probe binds is provided.
    Type: Grant
    Filed: June 30, 2011
    Date of Patent: January 28, 2014
    Assignee: Life Technologies Corporation
    Inventors: James P. Hoeffler, Joseph M. Fernandez, Marc S. Nasoff
  • Patent number: 8637265
    Abstract: Elevated levels of cathepsin E (catE) are demonstrated to be diagnostic of intestinal forms of cancer, such as colorectal cancer. Elevated levels of cathepsin E (catE, monomeric forms) are demonstrated to be detectable in the urine of animals having colorectal cancer, and a diagnostic/screening method for identifying and/or detecting colorectal cancer in an animal from a urine sample is provided. Specific tissue immunohistochemcial staining for catE (monomeric forms) in dysplastic tissue is also disclosed, and is shown to correlate with the level of dysplastic lesion severity. Hence, a method for identifying and determining the level of dysplastic lesion severity is provided. Cathepsin E mRNA transcription and expression levels are also demonstrated to be upregulated in dysplastic tissue, relative to non-dysplastic tissue. Hence, a method for transcriptionally profiling an animal to monitor the progression of colorectal disease is provided.
    Type: Grant
    Filed: December 28, 2010
    Date of Patent: January 28, 2014
    Assignee: University of Notre Dame
    Inventors: Rudolph M. Navari, Mary Prorok, Francis J. Castellino
  • Patent number: 8637266
    Abstract: Methods for identifying compounds useful for treating diseases and conditions of the oral cavity are described herein.
    Type: Grant
    Filed: April 1, 2010
    Date of Patent: January 28, 2014
    Assignee: Colgate-Palmolive Company
    Inventors: Virginia Barnes, Harsh M. Trivedi, Wei Wang, Tao Xu, Emi Shimizu, Nicola C. Partridge
  • Patent number: 8637267
    Abstract: Inhibitors of the tmRNA pathway have antibacterial activity with broad species specificity, including B. anthracis and other pathogens of military and civilian interest. Identified cyclic or linear peptides are further selected by in vivo selection methods, kill bacterial pathogens when added exogenously, and/or eliminate plasmids carrying antibiotic resistance or virulence genes. The molecular target of each cyclic peptide is in the tmRNA pathway and the tmRNA pathway is inhibited in vitro and in vivo by the addition of the peptides.
    Type: Grant
    Filed: April 28, 2008
    Date of Patent: January 28, 2014
    Assignee: The Penn State Research Foundation
    Inventors: Kenneth C. Keiler, Stephen J. Benkovic
  • Patent number: 8637268
    Abstract: Novel methods are described for measuring the rate of ADAMTS13-mediated cleavage of von Willebrand Factor (VWF) multimers. Through the use of the reagent, ristocetin, the method can advantageously be performed in the absence of an applied shear stress or added denaturing agent. Also described are methods for diagnosing ADAMTS13-associated disorders and methods for providing improved treatment of those disorders by evaluating the efficacy of the treatment using the methods as described.
    Type: Grant
    Filed: November 4, 2011
    Date of Patent: January 28, 2014
    Assignee: Puget Sound Blood Center
    Inventors: Junmei Chen, Dominic W. Chung, Jose Aron Lopez
  • Patent number: 8637269
    Abstract: Melamine is a common industrial chemical contaminant which should be absent from food and feed supplies due to melamine's toxicity. Provided is a method to assess the presence of melamine in samples prepared from compositions. The method may include using a microbial enzyme called melamine deaminase which hydrolyzes melamine to ammeline and ammonia. The method may include assessing the presence of any ammonia produced from an enzymatic reaction between the sample and the enzyme.
    Type: Grant
    Filed: July 9, 2010
    Date of Patent: January 28, 2014
    Assignee: Bioo Scientific Corporation
    Inventor: Joseph Francis Krebs
  • Patent number: 8637270
    Abstract: The present invention is generally directed to a fluidized bed detector for continuous detection of biological and chemical materials comprising a fluidized bed of detecting elements suspended in a continuous flow system wherein the detecting elements remain in the system when a first force trying to move the detecting elements to the bottom of the system is balanced with a second opposing force of a flowing gas or liquid trying to move detecting elements to the top of the system and wherein the presence of a target molecule in the flowing gas or liquid disrupts the balance of the first and second forces causing the detecting element to exit the system. The release of the detecting element indicates the presence of the target molecule and may be captured, concentrated, or both for further evaluation by other assays or other means. Also disclosed is the related method of detecting biological and chemical materials using a fluidized bed detector.
    Type: Grant
    Filed: November 13, 2009
    Date of Patent: January 28, 2014
    Assignee: The United States of America, as represented by the Secretary of the Navy
    Inventor: David A Kidwell
  • Patent number: 8637271
    Abstract: Polymeric indicators are provided for visually monitoring, detecting, and/or determining the presence of metabolic byproducts from harmful or potentially harmful microorganisms.
    Type: Grant
    Filed: November 5, 2008
    Date of Patent: January 28, 2014
    Assignee: Indicator Systems International, Inc.
    Inventors: Jon Booher, Joel R. Gorski
  • Patent number: 8637272
    Abstract: The present invention provides an industrially useful improved halohydrin epoxidase, a method for producing the same, and a method for producing an epihalohydrin or 4-halo-3-hydroxybutyronitrile using the same. The improved halohydrin epoxidase of the present invention consists of an amino acid sequence in which a specific amino acid substitution mutation is introduced into an amino acid sequence of a wild-type halohydrin epoxidase comprising predetermined amino acid sequences I and II.
    Type: Grant
    Filed: March 7, 2008
    Date of Patent: January 28, 2014
    Assignee: Mitsubishi Rayon Co., Ltd.
    Inventors: Takanori Akiyama, Yu Fujio, Fumiaki Watanabe, Yuya Takikawa, Eiji Sato
  • Patent number: 8637273
    Abstract: The present invention provides antagonizing antibodies that bind to interleukin-7 receptor (IL-7R). The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acids. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof for the treatment and/or prevention of type 2 diabetes and immunological disorders, including type 1 diabetes, multiple sclerosis, rheumatoid arthritis, graft-versus-host disease, and lupus.
    Type: Grant
    Filed: September 26, 2012
    Date of Patent: January 28, 2014
    Assignee: Rinat Neuroscience Corp.
    Inventors: Chia-Yang Lin, Li-Fen Lee, Wenwu Zhai
  • Patent number: 8637274
    Abstract: It is intended to provide an inhibitor for the formation of a ?-secretase complex which comprises a cholesterol synthesis inhibitor or a protein geranylgeranylation regulator as the active ingredient; and use of a cholesterol synthesis inhibitor or a protein geranylgeranylation regulator for producing the same. It is also intended to provide a method of screening a substance having an effect of inhibiting the formation of an active complex of ?-secretase which comprises assaying the activity of inhibiting cholesterol synthesis or quantifying cholesterol accumulated in lipid rafts in cells. It is also intended to provide a method of screening a cholesterol synthesis inhibitor, a protein geranylgeranylation regulator or an HMG-CoA reductase inhibitor which comprises assaying the effect of inhibiting the formation of an active complex of ?-secretase.
    Type: Grant
    Filed: October 27, 2009
    Date of Patent: January 28, 2014
    Assignees: Kowa Company, Ltd., Nissan Chemical Industries, Ltd.
    Inventors: Yasuomi Urano, Takao Hamakubo, Tatsuhiko Kodama
  • Patent number: 8637275
    Abstract: A new method of diagnosing postprandial hyperglycemia by indirectly measuring a blood glucose level is provided. Postprandial hyperglycemia is detected by measuring a glycation degree of lysine in hemoglobin, in which a side chain amino group of lysine is glycated (GHbLys %). Measurement of GHbLys % can be performed by cleaving hemoglobin by protease, treating a glycated part of a lysine residue in the obtained cleavage product of hemoglobin with fructosyl amino acid oxidase, and measuring a redox reaction between the glycated part and fructosyl amino acid oxidase.
    Type: Grant
    Filed: August 10, 2007
    Date of Patent: January 28, 2014
    Assignee: ARKRAY, Inc.
    Inventors: Satoshi Yonehara, Toshihiro Imai
  • Patent number: 8637276
    Abstract: The present invention provides compositions, methods and kits for use in the detection of small RNA sequences, which allow for rapid and robust amplification and detection. The methods provide improved sensitivity and efficiency in the amplification-based detection of small RNA sequences by incorporating one or more base-modified duplex-stabilizing dNTPs during reverse transcription and/or amplification.
    Type: Grant
    Filed: October 8, 2008
    Date of Patent: January 28, 2014
    Inventor: Igor Vassily Kutyavin
  • Patent number: 8637277
    Abstract: The present invention provides is a method for producing 3-mercaptopropionic acid from 3-mercaptopropionamide or a salt thereof with the use of an amidase. The method enables the production of 3-mercaptopropionic acid on an industrial scale through an enzymatic reaction.
    Type: Grant
    Filed: April 30, 2010
    Date of Patent: January 28, 2014
    Assignee: Mitsui Chemicals, Inc.
    Inventors: Tadashi Araki, Masayuki Furuya, Hidetoshi Hayashi
  • Patent number: 8637278
    Abstract: The invention relates to a method for the enzymatic production of emulsifiers containing mono- and diacylglycerides. In a first step a), a mixture of a phospholipid component and a triacylglyceride component is prepared, then in step b) a quantity of an aqueous solution containing a (phospho)lipase is added to the mixture obtained, to produce a water content of the mixture of between 3 and 15 wt. %. In a subsequent step c), the mixture obtained in the previous step is reacted at a temperature ranging between 20° and 80° C. over a period of at least two hours and said mixture is then dried.
    Type: Grant
    Filed: September 2, 2004
    Date of Patent: January 28, 2014
    Assignee: Satia GmbH
    Inventors: Michael Volland, Thomas Lötzbeyer, Volker Sieber, Eva Wittmann
  • Patent number: 8637279
    Abstract: Disclosed herein is a recombinant Escherichia coli (E. coli) capable of producing D-xylonic acid from D-xylose and a method for producing D-xylonic acid using the same. The recombinant E. coli producing D-xylonic acid from D-xylose according to the present invention is a recombinant E. coli EWX4 (Microorganism deposition number KCTC11988BP) capable of producing D-xylonic acid from D-xylose. When utilizing the recombinant E. coli prepared by the method of the present invention, it is possible to produce D-xylonic acid from D-xylose with high yield while reducing production cost using sole carbon source.
    Type: Grant
    Filed: August 21, 2012
    Date of Patent: January 28, 2014
    Assignee: Myongji University Industry and Academia Cooperation Foundation
    Inventors: Wook-Jin Chung, Huaiwei Liu, Kris Niño Gomez Valdehuesa, Kristine Rose Medina Ramos, Mi-Deok Han
  • Patent number: 8637280
    Abstract: The present invention relates to newly identified genes that encode proteins that are involved in the (bio)synthesis of citric acid. The invention also features polynucleotides comprising the full-length polynucleotide sequences of the novel genes and fragments thereof, the novel polypeptides encoded by the polynucleotides and fragments thereof, as well as their functional equivalents. The present invention also relates to the use of said polynucleotides and polypeptides as biotechnological tools in the production of citric acid from microorganisms, whereby a modification of said polynucleotides and/or encoded polypeptides has a direct or indirect impact on yield, production, and/or efficiency of production of the fermentation product in said microorganism. Also included are methods/processes of using the polynucleotides and modified polynucleotide sequences to transform host microorganisms. The invention also relates to genetically engineered microorganisms and their use for production of citric acid.
    Type: Grant
    Filed: December 1, 2006
    Date of Patent: January 28, 2014
    Assignee: Adcuram Nutrition Holding GmbH
    Inventors: Hugo Marc Karel Bauweleers, Dominique Robert Groeseneken, Noël Nicolaas Maria Elisabeth Van Peij
  • Patent number: 8637281
    Abstract: Lactic acid bacterial (LAB) cells were modified such that they have a specific activity of dihydroxy-acid dehydratase enzyme activity that is increased to about 0.1 ?mol min?1 mg?1. LAB cells with even higher activities of 0.2 to 0.6 ?mol min?1 mg?1 of DHAD activity were obtained. These modified cells may be used to produce isobutanol when additional isobutanol biosynthetic pathway enzymes are expressed.
    Type: Grant
    Filed: September 29, 2009
    Date of Patent: January 28, 2014
    Assignee: Butamax(TM) Advanced Biofuels LLC
    Inventors: Brian James Paul, Wonchul Suh
  • Patent number: 8637282
    Abstract: Methods are provided for the efficient fractionation of lignocellulosic biomasses into cellulosic, hemicellulosic and lignin fractions, wherein concentrated organic acid vapors are applied to the biomass at elevated temperatures at the location(s) or near the location(s) where the biomass has been harvested and gathered, to at least partly depolymerize or substantially solubilize the hemicelluloses and lignins in the biomass. The organic acid-treated biomass is in either case then dried and pelletized for extended bulk storage and/or for shipment to a second facility some distance away. The organic acid-treated biomass may be processed into desired chemicals, fuels and/or fuel additives at the local processing site or at a second facility away from the local processing site, or the pelletized material may be used as a ruminant feed locally or at a feedlot some distance removed from the local processing site.
    Type: Grant
    Filed: January 21, 2011
    Date of Patent: January 28, 2014
    Assignee: Archer Daniels Midland Company
    Inventors: Thomas P. Binder, Paul D. Bloom, Perry H. Doane, Chi-Cheng Ma
  • Patent number: 8637283
    Abstract: A recombinant microorganism employing a bacterial pathway to produce a cyclic amino acid (e.g., coronamic acid or norcoronamic acid) and a plant enzyme (ACC oxidase) to oxidize the amino acid and produce an alkene (e.g., 1-butene or propene) is provided herein. Expression of these two biosynthetic modules in various microbial chassis will facilitate alkene production from diverse energy and carbon sources, including sugars, glycerol, CO2, CH4, H2, and sunlight.
    Type: Grant
    Filed: January 13, 2011
    Date of Patent: January 28, 2014
    Assignee: Mogene LC
    Inventors: Abhay Kumar Singh, Ganesh M. Kishore
  • Patent number: 8637284
    Abstract: Biomass (e.g., plant biomass, animal biomass, microbial, and municipal waste biomass) is processed to produce useful products, such as food products and amino acids.
    Type: Grant
    Filed: December 6, 2011
    Date of Patent: January 28, 2014
    Assignee: Xyleco, Inc.
    Inventor: Marshall Medoff
  • Patent number: 8637285
    Abstract: The present invention relates to a method by which a controlled source of heat (preferably a laser 3) generates a pulsating vapor bubble 4 in an enclosed liquid. The pulsating rate (the frequency) is preferably in the ultrasonic region, whereby cavitation occurs in the liquid. The cavitation effect will cause disruption of suspended components such as cells or bacterial spores. The ultrasonic disruption of cellular components is known as lysing by sonication.
    Type: Grant
    Filed: December 23, 2005
    Date of Patent: January 28, 2014
    Assignee: Memsflow ApS
    Inventor: Tomas Ussing
  • Patent number: 8637286
    Abstract: A non-naturally occurring microbial organism includes a microbial organism having a reductive TCA or Wood-Ljungdahl pathway in which at least one exogenous nucleic acid encoding these pathway enzymes is expressed in a sufficient amount to enhance carbon flux through acetyl-CoA. A method for enhancing carbon flux through acetyl-CoA includes culturing theses non-naturally occurring microbial organisms under conditions and for a sufficient period of time to produce a product having acetyl-CoA as a building block. Another non-naturally occurring microbial organism includes at least one exogenous nucleic acid encoding an enzyme expressed in a sufficient amount to enhance the availability of reducing equivalents in the presence of carbon monoxide or hydrogen, thereby increasing the yield of redox-limited products via carbohydrate-based carbon feedstock.
    Type: Grant
    Filed: January 21, 2011
    Date of Patent: January 28, 2014
    Assignee: Genomatica, Inc.
    Inventors: Anthony P. Burgard, Robin E. Osterhout, Jun Sun, Priti Pharkya
  • Patent number: 8637287
    Abstract: The present invention generally relates to materials and methods for exploiting glycosyltransferase reversibility for nucleotide diphosphate (NDP) sugar synthesis. The present invention provides engineered glycosyltransferase enzymes characterized by improved reaction reversibility and expanded sugar donor specificity as compared to corresponding non-mutated glycosyltransferase enzymes. Such reagents provide advantageous routes to NDP sugars for subsequent use in a variety of biomedical applications, including enzymatic and chemoenzymatic glycorandomization.
    Type: Grant
    Filed: June 13, 2011
    Date of Patent: January 28, 2014
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Jon S. Thorson, Richard W. Gantt
  • Patent number: 8637288
    Abstract: Novel thermostable chimeric nucleic acid polymerases and methods for their generation and use are disclosed. It is shown that these chimeric nucleic acid polymerases, such as DNA polymerases, can be constructed using enzymatically active domains, isolated from different proteins or chemically synthesized. It is demonstrated that chimeric nucleic acid polymerases of the present invention possess the chemical and physical properties of their component domains (e.g., exonuclease activity, thermostability) and that the chimeric polymerases are thermostable.
    Type: Grant
    Filed: August 8, 2002
    Date of Patent: January 28, 2014
    Assignee: Qiagen, GmbH
    Inventors: Dirk Löffert, Andreas Missel, Jie Kang
  • Patent number: 8637289
    Abstract: The invention relates to a recombinant host cell having (a) a modification in an endogenous polynucleotide encoding a polypeptide having dual-role hexokinase activity; (b) a heterologous polynucleotide encoding a polypeptide having hexose kinase activity; and optionally (c) a modification in an endogenous polynucleotide encoding a polypeptide having pyruvate decarboxylase activity. Additionally, the invention relates to methods of making and using such recombinant host cells including, for example, methods of increasing glucose consumption, methods of improving redox balance, and/or methods of increasing the production of a product of a pyruvate-utilizing pathway.
    Type: Grant
    Filed: December 29, 2010
    Date of Patent: January 28, 2014
    Assignee: Butamax(TM) Advanced Biofuels LLC
    Inventors: Larry Cameron Anthony, Arthur Leo Kruckeberg
  • Patent number: 8637290
    Abstract: The invention provides novel polypeptides having phospholipase activity, including, e.g., phospholipase A, B, C and D activity, patatin activity, phosphatidic acid phosphatases (PAP) and/or lipid acyl hydrolase (LAH) activity, nucleic acids encoding them and antibodies that bind to them. Industrial methods, e.g., oil degumming, and products comprising use of these phospholipases are also provided.
    Type: Grant
    Filed: September 21, 2007
    Date of Patent: January 28, 2014
    Assignee: DSM IP Assets B.V.
    Inventors: Eileen O'Donoghue, Nelson R. Barton